revuforj(revumenib)Medication DetailsSyndax Pharmaceuticals, Inc.Usage: REVUFORJ is indicated for treating relapsed or refractory acute leukemia with a KMT2A gene translocation in adults and pediatric patients aged 1 year and older.Medication DetailsDrug Interactions